Entera Bio Ltd. Cash Flow Statement
ENTX|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$7M
FY2025
Free Cash Flow
-$7M
FY2025
Capital Expenditures
$3,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Entera Bio Ltd. used $7M in operating cash flow and negative free cash flow of $7M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$9.5M | -$8.9M | -$13.1M | -$12.2M | -$11.2M |
| Depreciation & Amortization | $46.0K | $56.0K | $64.0K | $53.0K | $63.0K |
| Operating Cash Flow | -$6.8M | -$7.3M | -$12.5M | -$9.1M | -$10.6M |
| Capital Expenditures | $3.0K | $17.0K | $47.0K | $17.0K | $53.0K |
| Free Cash Flow | -$6.8M | -$7.3M | -$12.5M | -$9.1M | -$10.6M |
| FCF Margin | -3768.5% | - | -9362.7% | -1590.2% | -2906.8% |